Gastrointestinal stromal tumors (GISTs) are the most common malignant subepithelial
lesions (SELs) of the gastrointestinal tract. They originate from the interstitial cells of Cajal …

Abstract Background Gastrointestinal stromal tumours (GISTs) are rare, yet the most
common mesenchymal tumour within the digestive tract. Lack of diagnostic criteria and no …

Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the
gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in …

Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …

Background The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery
needs to be estimated when considering adjuvant systemic therapy. We assessed …

PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for
advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch …

Background Prognosis of advanced gastrointestinal stromal tumors (GIST) refractory to
tyrosine kinase inhibitors (TKIs) is poor. This randomized, placebo-controlled, phase III trial …

INTRIGUE was an open-label, phase 3 study in adult patients with advanced gastrointestinal
stromal tumor who had disease progression on or intolerance to imatinib and who were …

Naturally occurring cancers in pet dogs and humans share many features, including
histological appearance, tumour genetics, molecular targets, biological behaviour and …

Importance Three years of adjuvant imatinib mesylate therapy is associated with reduced
recurrence rates and improved overall survival in patients with high-risk primary …